CRVO vs. ACHL, FGEN, IMMX, LTRN, RPTX, PRLD, RNTX, KALA, CNTB, and CELU
Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Achilles Therapeutics (ACHL), FibroGen (FGEN), Immix Biopharma (IMMX), Lantern Pharma (LTRN), Repare Therapeutics (RPTX), Prelude Therapeutics (PRLD), Rein Therapeutics (RNTX), KALA BIO (KALA), Connect Biopharma (CNTB), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry.
CervoMed vs.
Achilles Therapeutics (NASDAQ:ACHL) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
CervoMed has higher revenue and earnings than Achilles Therapeutics.
In the previous week, CervoMed had 4 more articles in the media than Achilles Therapeutics. MarketBeat recorded 4 mentions for CervoMed and 0 mentions for Achilles Therapeutics. CervoMed's average media sentiment score of 0.40 beat Achilles Therapeutics' score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.
Achilles Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 189.86%. CervoMed has a consensus price target of $37.43, suggesting a potential upside of 1,541.60%. Given CervoMed's higher possible upside, analysts clearly believe CervoMed is more favorable than Achilles Therapeutics.
Achilles Therapeutics received 3 more outperform votes than CervoMed when rated by MarketBeat users. However, 73.68% of users gave CervoMed an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
Achilles Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -118.68%. CervoMed's return on equity of -44.11% beat Achilles Therapeutics' return on equity.
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by insiders. Comparatively, 36.3% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Achilles Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
Summary
CervoMed beats Achilles Therapeutics on 12 of the 15 factors compared between the two stocks.
Get CervoMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CervoMed Competitors List
Related Companies and Tools
This page (NASDAQ:CRVO) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CRVO Stock Alerts